DM Clinical Research- Cyfair

Houston, Texas 77065

2 studies enrolling now · 17 studies all time

What they study most

Acute Gastroenteritis, COVID-19, COVID-19 (Coronavirus Disease 2019), Chikungunya Virus, Clostridioides Difficile Associated Disease, Healthy Participants, Influenza, Influenza, Human, Influenza,Human, Lower Respiratory Tract Illness, Migraine, Norovirus Acute Gastroenteritis

Studies at this site

• Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects — Recruiting now
• A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older — Recruiting now
• A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19 — Completed
• A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children — Completed
• A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults — Completed
• A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years — Completed
• A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis — Running, not enrolling
• A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age — Running, not enrolling
• Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. — Running, not enrolling
• A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People — Completed
• A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults — Completed
• A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age — Completed
• A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People — Completed
• A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus — Completed
• A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV). — Completed
• Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years — Completed
• A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old — Completed